NERV

Company Overview — What Does Minerva Neurosciences, Inc. Do?

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts. Minerva Neurosciences, Inc. (NERV) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Rémy H. Luthringer and employs approximately 9 people, headquartered in Cambridge, Massachusetts. With a market capitalization of $242M, NERV is one of the notable companies in the Healthcare sector.

Minerva Neurosciences, Inc. (NERV) Stock Rating — Reduce (April 2026)

As of April 2026, Minerva Neurosciences, Inc. receives a Reduce rating with a composite score of 34.3/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.NERV ranks #2,618 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Minerva Neurosciences, Inc. ranks #344 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

NERV Stock Price and 52-Week Range

Minerva Neurosciences, Inc. (NERV) currently trades at $5.62. The stock lost $0.40 (6.6%) in the most recent trading session. The 52-week high for NERV is $12.46, which means the stock is currently trading -54.9% from its annual peak. The 52-week low is $1.15, putting the stock 388.7% above its annual trough. Recent trading volume was 202K shares, suggesting relatively thin trading activity.

Is NERV Overvalued or Undervalued? — Valuation Analysis

Minerva Neurosciences, Inc. (NERV) carries a value factor score of 23/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 17.57x, compared to the Healthcare sector average of 23.63x — a discount of 26%.

At current multiples, Minerva Neurosciences, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Minerva Neurosciences, Inc. Profitability — ROE, Margins, and Quality Score

Minerva Neurosciences, Inc. (NERV) earns a quality factor score of 10/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 49.9%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 13.0% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

NERV Debt, Balance Sheet, and Financial Health

Minerva Neurosciences, Inc. has a debt-to-equity ratio of 0.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 36.28x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $12M.

NERV has a beta of 0.52, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Minerva Neurosciences, Inc. is 31/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Minerva Neurosciences, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Minerva Neurosciences, Inc. reported revenue of $0 and earnings per share (EPS) of $-34.67. Net income for the quarter was $13M. Operating income came in at $-14M.

In FY 2025, Minerva Neurosciences, Inc. reported revenue of $0 and earnings per share (EPS) of $-34.67. Net income for the quarter was $-293M. Operating income came in at $-15M.

In Q3 2025, Minerva Neurosciences, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.36. Net income for the quarter was $-3M. Operating income came in at $-3M.

In Q2 2025, Minerva Neurosciences, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.43. Net income for the quarter was $-3M. Operating income came in at $-3M.

Over the past 8 quarters, Minerva Neurosciences, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing NERV stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

NERV Dividend Yield and Income Analysis

Minerva Neurosciences, Inc. (NERV) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

NERV Momentum and Technical Analysis Profile

Minerva Neurosciences, Inc. (NERV) has a momentum factor score of 77/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 31/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

NERV vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Minerva Neurosciences, Inc. (NERV) ranks #344 out of 838 stocks based on the Blank Capital composite score. This places NERV in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing NERV against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full NERV vs S&P 500 (SPY) comparison to assess how Minerva Neurosciences, Inc. stacks up against the broader market across all factor dimensions.

NERV Next Earnings Date

No upcoming earnings date has been announced for Minerva Neurosciences, Inc. (NERV) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy NERV? — Investment Thesis Summary

The quantitative profile for Minerva Neurosciences, Inc. suggests caution. The quality score of 10/100 flags below-average profitability. The value score of 23/100 indicates premium valuation. Price momentum is positive at 77/100, suggesting the trend favors buyers. High volatility (stability score 31/100) increases portfolio risk.

In summary, Minerva Neurosciences, Inc. (NERV) earns a Reduce rating with a composite score of 34.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on NERV stock.

Related Resources for NERV Investors

Explore more research and tools: NERV vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare NERV head-to-head with peers: NERV vs AZN, NERV vs SLGL, NERV vs VMD.